QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.105.013086v1 68/4/1006    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Culmsee, C. Articles by Krieglstein, J. Search for Related Content PubMed PubMed Citation Articles by Culmsee, C. Articles by Krieglstein, J.

Nitric Oxide Donors Induce Neurotrophin-Like Survival Signaling and Protect Neurons against Apoptosis

Institute of Pharmacology and Toxicology, Department of Pharmacy, Philipps-University Marburg, Germany (C.C., N.G., J.K.); Pharmaceutical Biology-Biotechnology, Center of Drug Research, Department of Pharmacy, Ludwig-Maximilians-University Munich, Germany (C.C.); Pharmaceutical Chemistry, Department of Pharmacy, University of Hamburg, Germany (B.R., H.-J.D.); Department of Applied Chemistry, Faculty of Science and Technology, Keio University, Yokohama, Japan (K.U.); and Institute of Pharmaceutical and Medicinal Chemistry, Westphalian Wilhelms-University Muenster, Germany (S.K.)

Our previous results showed that inhibition of protein tyrosine phosphatases (PTP) by orthovanadate is an appropriate strategy to mimic nerve growth factor (NGF) effects in neurons, including enhanced phosphorylation of TrkA, stimulation of downstream survival signaling pathways, and protection against apoptotic stress. In this study, we wanted to trigger such NGF-like survival signaling in primary hippocampal neurons with the more specific PTP inhibitors ethyl-3,4-dephostatin (DPN), 4-O-methyl-ethyl-3,4-dephostatin (Me-DPN), and methoxime-3,4-dephostatin. It was striking that only the nitric oxide (NO)-releasing dephostatin analogs DPN and Me-DPN, but not the nitrosamine-free methoxime derivative (which did not release NO), enhanced TrkA phosphorylation and protected the neurons against staurosporine (STS)-induced apoptosis. The established NO donor S-nitroso-N-acetylpenicillamine (SNAP) also enhanced TrkA phosphorylation and prevented apoptosis similarly to DPN and Me-DPN. Analysis of the major signaling pathways downstream of TrkA revealed that both SNAP and DPN enhanced phosphorylation of Akt and the mitogen-activated kinases (MAPK) Erk1/2. Blocking of these signaling pathways by the PI3-K inhibitor wortmannin or the MAPK kinase inhibitor U0126 [1,4-diamino-2,3-dicyano-1,4-bis(2-aminophynyltio)butadiene] equally abolished the neuroprotective effect of the NO donors. It was striking that inhibition of the soluble guanylyl cyclase (sGC) by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) or protein kinase G (PKG) inhibition by (9S,10R,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-2,9-dimethyl-1-oxo-9,12-epoxy-1H-diindolo-[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid methyl ester (KT5823) also blocked the neuroprotective effect of the NO donors, and ODQ clearly attenuated SNAP-induced phosphorylation of TrkA, Akt, and MAPK. In conclusion, NO release by the dephostatin derivatives and subsequent stimulation of sGC and PKG is essential for their neuroprotective effects. In primary neurons, such NO-activated survival signaling involves NGF-like effects, including enhanced phosphorylation of TrkA and activation of PI3-K/Akt and MAPK pathways.

Address correspondence to: Priv.-Doz. Dr. Carsten Culmsee, Pharmazeutische Biologie–Biotechnologie, Department Pharmazie, Zentrum für Arzneimittelforschung, Ludwig-Maximilians-Universität, Butenandtstraße 5-13, Gebäude D, D-81377 München, Germany. E-mail: carsten.culmsee{at}cup.unimuenchen.de

This article has been cited by other articles:

				C. J. Wruck, M. E. Gotz, T. Herdegen, D. Varoga, L.-O. Brandenburg, and T. Pufe Kavalactones Protect Neural Cells against Amyloid {beta} Peptide-Induced Neurotoxicity via Extracellular Signal-Regulated Kinase 1/2-Dependent Nuclear Factor Erythroid 2-Related Factor 2 Activation Mol. Pharmacol., June 1, 2008; 73(6): 1785 - 1795. [Abstract] [Full Text] [PDF]

				D. M. Wilcock, M. R. Lewis, W. E. Van Nostrand, J. Davis, M. L. Previti, N. Gharkholonarehe, M. P. Vitek, and C. A. Colton Progression of Amyloid Pathology to Alzheimer's Disease Pathology in an Amyloid Precursor Protein Transgenic Mouse Model by Removal of Nitric Oxide Synthase 2 J. Neurosci., February 13, 2008; 28(7): 1537 - 1545. [Abstract] [Full Text] [PDF]

				L. Ying, A. B. Hofseth, D. D. Browning, M. Nagarkatti, P. S. Nagarkatti, and L. J. Hofseth Nitric Oxide Inactivates the Retinoblastoma Pathway in Chronic Inflammation Cancer Res., October 1, 2007; 67(19): 9286 - 9293. [Abstract] [Full Text] [PDF]

				K. Akassoglou Nerve Growth Factor-Independent Neuronal Survival: A Role for NO Donors Mol. Pharmacol., October 1, 2005; 68(4): 952 - 955. [Abstract] [Full Text] [PDF]